Veracyte Inc (VCYT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 11:05 AM ET
Veracyte Inc (VCYT) Earnings: Report Dates and Results
Veracyte (VCYT) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Veracyte reported EPS of $0.38, above the $0.29 estimate. It beat the EPS estimate in each of the last 9 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VCYT has an expected report date of Feb 22, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 22.6% below the $0.53 reported for the quarter ended Dec 31, 2025.
VCYT Earnings Call
The latest VCYT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, VCYT beat 27, missed 10 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $151.75M, up 15.1% from $131.87M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.38 | $0.29 | N/A | +31.03% | Beat | -25.5% | 11 | 0 up, 1 down | Nov 4, 2026 | $151.75M |
| Jun 30, 2026 | $0.37 | $0.29 | N/A | +27.59% | Beat | -15.9% | 11 | 6 up, 2 down | Jul 30, 2026 | $150.32M |
| Mar 31, 2026 | $0.52 | $0.33 | $0.23 - $0.37 | +57.58% | Beat | +67.7% | 11 | 7 up, 3 down | May 5, 2026 | $139.07M |
| Dec 31, 2025 | $0.53 | $0.39 | $0.37 - $0.46 | +35.90% | Beat | +47.2% | 10 | 5 up, 0 down | Feb 25, 2026 | $140.64M |
| Sep 30, 2025 | $0.51 | $0.32 | $0.30 - $0.35 | +59.38% | Beat | +54.5% | 11 | 0 up, 0 down | Nov 4, 2025 | $131.87M |
| Jun 30, 2025 | $0.44 | $0.30 | $0.25 - $0.34 | +46.67% | Beat | +46.7% | 8 | 3 up, 3 down | Aug 6, 2025 | $130.16M |
| Mar 31, 2025 | $0.31 | $0.20 | $0.15 - $0.25 | +55.00% | Beat | +675.0% | 11 | 0 up, 2 down | May 7, 2025 | $114.47M |
| Dec 31, 2024 | $0.36 | $0.26 | $0.12 - $0.30 | +40.02% | Beat | N/A | 10 | 7 up, 1 down | Feb 24, 2025 | $118.63M |
| Sep 30, 2024 | $0.33 | $0.17 | N/A | +94.12% | Beat | N/A | 7 | 2 up, 0 down | Nov 6, 2024 | $115.86M |
| Jun 30, 2024 | $0.30 | -$0.01 | -$0.06 - $0.06 | N/A | N/A | N/A | 8 | 1 up, 0 down | Aug 6, 2024 | $114.43M |
| Mar 31, 2024 | $0.04 | -$0.10 | N/A | +140.00% | Beat | N/A | 6 | 1 up, 0 down | May 7, 2024 | $96.84M |
| Dec 31, 2023 | -$0.39 | -$0.09 | -$0.14 - -$0.06 | -333.33% | Miss | N/A | 6 | 2 up, 0 down | Feb 22, 2024 | $98.20M |
| Sep 30, 2023 | -$0.41 | -$0.13 | -$0.17 - -$0.12 | -215.38% | Miss | N/A | 8 | 0 up, 0 down | Nov 7, 2023 | $90.11M |
| Jun 30, 2023 | -$0.12 | -$0.14 | -$0.17 - -$0.12 | +14.29% | Beat | N/A | 8 | 0 up, 0 down | Aug 8, 2023 | $90.32M |
| Mar 31, 2023 | -$0.11 | -$0.11 | -$0.17 - -$0.05 | 0.00% | In line | N/A | 8 | 1 up, 1 down | May 4, 2023 | $82.42M |
| Dec 31, 2022 | -$0.05 | -$0.15 | -$0.20 - -$0.11 | +66.67% | Beat | N/A | 7 | 1 up, 0 down | Feb 22, 2023 | $80.30M |
| Sep 30, 2022 | -$0.12 | -$0.23 | -$0.29 - -$0.19 | +47.83% | Beat | N/A | 7 | 0 up, 1 down | Nov 2, 2022 | $75.59M |
| Jun 30, 2022 | -$0.13 | -$0.22 | -$0.27 - -$0.17 | +40.91% | Beat | N/A | 7 | 0 up, 0 down | Aug 2, 2022 | $72.86M |
| Mar 31, 2022 | -$0.20 | -$0.23 | -$0.29 - -$0.19 | +13.04% | Beat | N/A | 9 | 0 up, 0 down | May 3, 2022 | $67.78M |
| Dec 31, 2021 | -$0.15 | -$0.16 | -$0.22 - -$0.06 | +6.25% | Beat | N/A | 9 | N/A | Feb 28, 2022 | $67.34M |
| Sep 30, 2021 | -$0.20 | -$0.14 | -$0.22 - -$0.08 | -42.86% | Miss | N/A | 8 | N/A | Nov 9, 2021 | $60.37M |
| Jun 30, 2021 | -$0.13 | -$0.25 | -$0.30 - -$0.21 | +48.00% | Beat | N/A | 10 | N/A | Jul 29, 2021 | $55.10M |
| Mar 31, 2021 | -$0.66 | -$0.12 | -$0.17 - -$0.05 | -450.00% | Miss | N/A | 8 | N/A | May 10, 2021 | $36.70M |
| Dec 31, 2020 | -$0.14 | -$0.10 | -$0.18 - -$0.06 | -40.00% | Miss | N/A | 8 | N/A | Feb 17, 2021 | $34.54M |
| Sep 30, 2020 | -$0.08 | -$0.19 | -$0.25 - -$0.17 | +57.89% | Beat | N/A | 6 | N/A | Nov 2, 2020 | $31.12M |
| Jun 30, 2020 | -$0.22 | -$0.27 | -$0.34 - -$0.13 | +18.52% | Beat | N/A | 5 | N/A | Jul 30, 2020 | $20.70M |
| Mar 31, 2020 | -$0.24 | -$0.20 | -$0.27 - -$0.15 | -20.00% | Miss | N/A | 6 | N/A | May 6, 2020 | $31.12M |
| Dec 31, 2019 | -$0.15 | -$0.07 | -$0.09 - -$0.06 | -114.29% | Miss | N/A | 6 | N/A | Feb 25, 2020 | $29.73M |
| Sep 30, 2019 | -$0.02 | -$0.07 | -$0.12 - -$0.04 | +71.43% | Beat | N/A | 6 | N/A | Oct 22, 2019 | $30.97M |
| Jun 30, 2019 | -$0.05 | -$0.09 | -$0.14 - -$0.07 | +44.44% | Beat | N/A | 5 | N/A | Jul 30, 2019 | $30.14M |
| Mar 31, 2019 | -$0.05 | -$0.07 | -$0.18 - -$0.02 | +28.57% | Beat | N/A | 4 | N/A | Apr 30, 2019 | $29.53M |
| Dec 31, 2018 | -$0.08 | -$0.15 | -$0.19 - -$0.10 | +46.67% | Beat | N/A | 4 | N/A | Feb 25, 2019 | $25.75M |
| Sep 30, 2018 | -$0.12 | -$0.21 | N/A | +42.86% | Beat | N/A | 4 | N/A | Oct 29, 2018 | $23.47M |
| Jun 30, 2018 | -$0.18 | -$0.26 | -$0.30 - -$0.23 | +30.77% | Beat | N/A | 5 | N/A | Jul 23, 2018 | $22.75M |
| Mar 31, 2018 | -$0.27 | -$0.25 | -$0.27 - -$0.22 | -8.00% | Miss | N/A | 5 | N/A | May 1, 2018 | $20.04M |
| Dec 31, 2017 | -$0.24 | -$0.20 | -$0.24 - -$0.18 | -20.00% | Miss | N/A | 5 | N/A | Feb 27, 2018 | $19.60M |
| Sep 30, 2017 | -$0.21 | -$0.21 | -$0.32 - -$0.19 | 0.00% | In line | N/A | 6 | N/A | Nov 6, 2017 | $17.52M |
| Jun 30, 2017 | -$0.22 | -$0.25 | -$0.27 - -$0.22 | +12.00% | Beat | N/A | 4 | N/A | Jul 31, 2017 | $18.41M |
| Mar 31, 2017 | -$0.24 | -$0.23 | N/A | -4.35% | Miss | N/A | N/A | N/A | May 3, 2017 | $16.43M |
| Dec 31, 2016 | -$0.14 | -$0.26 | N/A | +46.15% | Beat | N/A | N/A | N/A | Mar 1, 2017 | $18.26M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $1.79, up 73.8% from the year before. It was -$1.10 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $1.79 | +73.8% |
| Dec 31, 2024 | $1.03 | N/A |
| Dec 31, 2023 | -$1.03 | N/A |
| Dec 31, 2022 | -$0.50 | N/A |
| Dec 31, 2021 | -$1.14 | N/A |
| Dec 31, 2020 | -$0.68 | N/A |
| Dec 31, 2019 | -$0.27 | N/A |
| Dec 31, 2018 | -$0.65 | N/A |
| Dec 31, 2017 | -$0.91 | N/A |
| Dec 31, 2016 | -$1.10 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,800 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,820 | 14 | |
| 2026Q2 | Jun 30, 2026 | 8,174 | 14 | |
| 2026Q1 | Mar 31, 2026 | 5,748 | 10 | |
| 2025Q4 | Dec 31, 2025 | 9,365 | 16 | |
| 2025Q3 | Sep 30, 2025 | 7,158 | 14 | |
| 2025Q2 | Jun 30, 2025 | 8,915 | 15 | |
| 2025Q1 | Mar 31, 2025 | 10,155 | 13 | |
| 2024Q4 | Dec 31, 2024 | 8,937 | 14 |
2026Q3 Earnings Call
Opening remarks
Kelly Gura Director of Investor Relations Good afternoon, everyone, and thank you for joining us today to review Veracyte's third quarter 2026 financial results. Joining me on the call are Marc A. Stapley, our Chief Executive Officer, and Rebecca Chambers, our Chief Financial Officer. Dr. John Leite, our Chief Commercial Officer, will also be available for Q&A. Earlier this afternoon, we issued a press release detailing our third quarter financial results, and we posted an accompanying presentation in the Investors section of our website. Before we begin, I would like to remind you that statements we make during this call include forward-looking statements, as defined under applicable securities laws. Forward-looking statements are subject to risks and uncertainties, and the company can give no assurance that they will prove to be correct. The company undertakes no obligation to update any forward-looking statements, except as required by law. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to the documents that Veracyte files with the Securities and Exchange Commission, including the most recent Forms 10-Q and 10-K. In addition, this call will include certain non-GAAP financial measures. Reconciliations of these measures to the most directly comparable GAAP financial measures are included in today's earnings release, accessible from the Investors section of Veracyte's website. I will now turn the call over to Marc A. Stapley, Veracyte's CEO.
Marc A. Stapley CEO Thank you, Kelly, and thank you all for joining us today. Third quarter revenue increased 15% year over year to $152 million, and we delivered another quarter of strong profitability and cash generation. Afirma exceeded expectations, while Decipher prostate volume was lower than we expected. Today, we will share our observations regarding these trends, the steps we are taking to support future growth, and why we remain confident in the long-term opportunity for all of our tests. First, I would like to highlight some of the exciting momentum we are seeing across our portfolio. We have made good progress advancing our breast and bladder strategies over the last few months, with the launches of Prosigna LDT for breast cancer and TruMRD for muscle-invasive bladder cancer, or MIBC. In September, we strengthened our urology portfolio through the acquisition of Convergent Genomics, adding a technology platform that complements our tissue- and blood-based capabilities across the bladder cancer continuum. We also advanced our market access strategies in breast, prostate, and bladder cancer, helping preserve and expand access to our valuable tests for Medicare-eligible patients. Now I will walk through our performance across each of our growth drivers. Starting with Decipher Prostate, we delivered nearly 30,000 tests in the third quarter, representing 12% year-over-year growth, with volume approximately 1,000 tests lower than we expected.
Frequently Asked Questions About VCYT
When is Veracyte's next earnings date?
Veracyte's next earnings report is expected for Feb 22, 2027.
Did VCYT beat earnings estimates last quarter?
Yes. Veracyte reported EPS of $0.38 for the quarter ended Sep 30, 2026, above the $0.29 estimate, a 31.03% surprise.
What EPS do analysts expect from VCYT next quarter?
The consensus EPS estimate for Veracyte for the quarter ending Dec 31, 2026 is $0.41 from 14 analysts, with estimates from $0.30 to $0.53.
How often does VCYT beat earnings estimates?
Veracyte beat the EPS estimate in each of the last 9 quarters, with an average surprise of +49.70%.
VCYT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts